News

Nexavar® approved in Japan

Bayer has been granted marketing approval for Nexavar® in Japan for the treatment of advanced renal cell carcinoma, the most common form of kidney cancer. Nexavar® is an oral multi-kinase inhibitor, jointly developed by Bayer HealthCare and Onyx Pharmaceuticals, that targets both the tumor cell and the tumor vasculature. » more

Protect potatoes from late blight
Fungicidal active ingredient receives registrations
Fluopicolide, the latest active ingredient in the Bayer CropScience fungicides portfolio, has received regulatory approval in Japan and the United States. » more

Protecting the climate
New biofuel source offers great potential
Bayer CropScience AG and other companies plan to jointly explore the potential for Jatropha in the biodiesel industry. » more

Baytubes®
Carbon nanotubes for new thermoplastic materials
The excellent electrical conductivity and mechanical strength of Baytubes® carbon nanotubes were the decisive factors leading to a cooperation agreement. » more